SCHEMBL164881

SCHEMBL164881

NC(=O)c1ccccc1-c1ccncc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCAT2 O15382 1/20 0.71
IKBKB O14920 3/20 0.58
CHUK O15111 3/20 0.58
IKBKE Q14164 1/20 0.58
PKMYT1 Q99640 1/20 0.58
ALDH1A1 P00352 1/20 0.54
CSNK1A1 P48729 1/20 0.51
TYRO3 Q06418 1/20 0.51
DYRK1B Q9Y463 1/20 0.51
CDC7 O00311 7/20 0.51
CASP1 P29466 1/20 0.50
CCNA2 P20248 1/20 0.50
CDK2 P24941 1/20 0.50
CCNA1 P78396 1/20 0.50
PLK4 O00444 1/20 0.49
MAPK13 O15264 1/20 0.49
DYRK3 O43781 1/20 0.49
ROCK2 O75116 1/20 0.49
RPS6KA5 O75582 1/20 0.49
PRKD3 O94806 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL9027847 0.98 BCAT2 (0.69) BCAT2IKBKBCHUKIKBKEPKMYT1
Hydrochloric Acid SCHEMBL4597839 0.98 BCAT2 (0.69) BCAT2IKBKBCHUKIKBKEPKMYT1
Hydrochloric Acid SCHEMBL29710331 0.98 BCAT2 (0.69) BCAT2IKBKBCHUKIKBKEPKMYT1
SCHEMBL6448102 0.96 BCAT2 (0.67) BCAT2IKBKBCHUKIKBKEPKMYT1
Pyridine SCHEMBL28666919 0.89 BCAT2 (0.79) BCAT2IKBKBCHUKIKBKEPKMYT1
SCHEMBL28529048 0.86 CHUK (0.56) BCAT2IKBKBCHUKIKBKEPKMYT1
SCHEMBL5878337 0.86 BCAT2 (0.87) BCAT2IKBKBALDH1A1CSNK1A1TYRO3
SCHEMBL7143118 0.84 CHUK (0.61) BCAT2IKBKBCHUKIKBKEPKMYT1
SCHEMBL30582476 0.84 BCAT2 (0.83) BCAT2IKBKBCHUKALDH1A1CSNK1A1
SCHEMBL132986 0.84 BCAT2 (1.00) BCAT2IKBKBCHUKIKBKEPKMYT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3259256-A1 COMPOUNDS AND METHODS FOR INDUCING BROWNING OF WHITE ADIPOSE TISSUE Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences (CN) 2017-12-27 EP claimed
CN-104086482-B Chemical molecules inhibiting the splicing mechanism for the treatment of diseases caused by splicing abnormalities 国家科研中心 2017-10-13 CN claimed
WO-2016131192-A1 COMPOUNDS AND METHODS FOR INDUCING BROWNING OF WHITE ADIPOSE TISSUE GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES (CN) 2016-08-25 WO claimed
WO-2011011514-A1 HETEROARYL BENZAMIDES, COMPOSITIONS AND METHODS OF USE THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2011-01-27 WO claimed
CN-101287707-A Kinase inhibitors DEVGEN NV (BE) 2008-10-15 CN claimed
EP-1934181-A2 KINASE INHIBITORS Devgen NV (BE) 2008-06-25 EP claimed
EP-1907362-A1 AMIDE DERIVATIVES AS KINASE INHIBITORS Devgen NV (BE) 2008-04-09 EP claimed
WO-2007042321-A2 KINASE INHIBITORS DEVGEN N.V. (BE) 2007-04-19 WO claimed
WO-2007006547-A1 AMIDE DERIVATIVES AS KINASE INHIBITORS DEVGEN N.V. (BE) 2007-01-18 WO claimed
EP-1715862-A1 KINASE INHIBITORS Devgen NV (BE) 2006-11-02 EP claimed
WO-2005082367-A1 KINASE INHIBITORS DEVGEN NV (BE) 2005-09-09 WO claimed
WO-1993006084-A1 BENZANILIDE DERIVATIVES AS 5-HT1D ANTAGONISTS GLAXO GROUP LIMITED (GB) 1993-04-01 WO claimed
US-12365681-B2 Dihydrobenzimidazolones for medical treatment C4 THERAPEUTICS, INC. (US) 2025-07-22 US disclosed
US-20240109889-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2024-04-04 US disclosed
US-11787802-B2 Dihydrobenzimidazolones for medical treatment C4 THERAPEUTICS, INC. (US) 2023-10-17 US disclosed
CN-114957250-B N- (9H-pyridine [2,3-b ] indol-4-yl) aryl carboxamide derivative and preparation method and application thereof 中国人民解放军北部战区总医院 2023-05-09 CN disclosed
EP-1421057-A1 CHEMOTHERAPEUTIC AGENTS Starpharma Limited (AU) 2004-05-26 EP disclosed
WO-2003018536-A1 CHEMOTHERAPEUTIC AGENTS STARPHARMA LIMITED (AU) 2003-03-06 WO disclosed
US-20020156281-A1 Amide inhibitors of microsomal triglyceride transfer protein BOOTH RICHARD JOHN (US) 2002-10-24 US disclosed
CN-1236358-A Substituted N-[(aminoiminomethyl or aminomethyl) phenyl] propyl amides RHONE POULENC RORER PHARMA (US) 1999-11-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020156281-A1 Amide inhibitors of microsomal triglyceride transfer protein CETP, MTTP, LCAT BCAT2 330/4885IKBKB 1557/4885CHUK 768/4885
US-12365681-B2 Dihydrobenzimidazolones for medical treatment CRBN, CUL4A, ADRM1 BCAT2 2957/4885IKBKB 80/4885CHUK 136/4885
US-20240109889-A1 DIHYDROBENZIMIDAZOLONES FOR MEDICAL TREATMENT CRBN, CUL4A, ADRM1 BCAT2 2957/4885IKBKB 80/4885CHUK 136/4885
US-11787802-B2 Dihydrobenzimidazolones for medical treatment CRBN, CUL4A, ADRM1 BCAT2 2957/4885IKBKB 80/4885CHUK 136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.